Page last updated: 2024-09-04

tipifarnib and Triple Negative Breast Neoplasms

tipifarnib has been researched along with Triple Negative Breast Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hanai, J; Ikegami, Y; Kaneki, M; Kuriyama, N; Nakazawa, H; Oki, M; Sukhatme, VP; Tanaka, T	1

Other Studies

1 other study(ies) available for tipifarnib and Triple Negative Breast Neoplasms

Article	Year
Low-Dose Farnesyltransferase Inhibitor Suppresses HIF-1α and Snail Expression in Triple-Negative Breast Cancer MDA-MB-231 Cells In Vitro. Journal of cellular physiology, 2017, Volume: 232, Issue:1 Topics: Cadherins; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Farnesyltranstransferase; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Quinolones; Receptors, Estrogen; Signal Transduction; Triple Negative Breast Neoplasms	2017

Article

Year

Low-Dose Farnesyltransferase Inhibitor Suppresses HIF-1α and Snail Expression in Triple-Negative Breast Cancer MDA-MB-231 Cells In Vitro.

Journal of cellular physiology, 2017, Volume: 232, Issue:1

Topics: Cadherins; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Farnesyltranstransferase; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Quinolones; Receptors, Estrogen; Signal Transduction; Triple Negative Breast Neoplasms

2017